Item 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

As of March 31, 2026, we had performed an evaluation, under the supervision of our principal executive officers and principal

financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. These controls and

procedures have been designed to ensure that information required for disclosure is recorded, processed, summarized, and reported

within the requisite time periods. Based on our evaluation, the principal executive officers and principal financial officer concluded that

our disclosure controls and procedures were effective as of March 31, 2026.

Changes in internal control over financial reporting

There has not been any change in our internal control over financial reporting during the three months ended March 31, 2026

that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Stockholder Matters

On November 25, 2025, a securities class action was filed against the Company and certain of its officers and directors in the

United States District Court for the Central District of California. On April 15, 2026, the lead plaintiffs filed an amended complaint

alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, based on alleged

material misrepresentations and omissions related to the Company’s business performance and real estate impairment charges

(captioned Hern v. Alexandria Real Estate Equities, Inc., et al.). The amended complaint seeks damages and other relief on behalf of

investors who acquired the Company’s securities between January 30, 2024 and December 5, 2025. The Company does not believe

the amended complaint states any meritorious claims and intends to defend this case vigorously.

On February 3, 2026 and March 25, 2026, stockholder derivative actions were filed against certain officers and directors of the

Company, with the Company named as a nominal defendant, in the United States District Court for the District of Maryland (captioned

De Albuquerque Torres v. Alexandria Real Estate Equities, Inc., et al.) and the United States District Court for the Central District of

California (captioned Tabone v. Moglia, et al.). The derivative complaints allege violations of federal securities laws and breaches of

fiduciary duty based on allegations similar to those in the securities class action and seek damages and other relief on behalf of the

Company. On April 8, 2026, the Maryland derivative action was stayed pending resolution of any motion to dismiss in the securities

class action. The Company does not believe the derivative complaints state any meritorious claims and intends to defend these cases

vigorously.

At this time, we cannot predict the outcome of these matters or reasonably estimate the amount or range of any possible loss,

if any, and therefore we have not recorded an accrual related to these

matters.

Option Parcel Development at Alexandria Center**®** for Life Science – New York City Campus

Refer to “Other” in Note 3 – “Investments in real estate” to our unaudited consolidated financial statements for information

regarding litigation involving our subsidiary in connection with an option and ground lease for a development parcel at the Alexandria

Center® for Life Science – New York City campus.